ArticleBlood advances2019
Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients.
Open access · goldAbstract read
In one paragraph
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosis.HemaSphere · 2026Article
- Long-Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real-World Analysis.EJHaem · 2025Article
- Second malignancies among older patients with classical myeloproliferative neoplasms treated with ruxolitinib.Blood neoplasia · 2025Article
- Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib.EJHaem · 2025Article
- Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review.Dermatology and therapy · 2024Review
- Does Double Mean Trouble? Coexistence of Myeloproliferative and Lymphoproliferative Neoplasms.Journal of clinical medicine · 2024Article
- Genetic and immunohistochemical profiling of NK/T-cell lymphomas reveals prognostically relevant BCOR-MYC association.Blood advances · 2023Article
- A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.Blood advances · 2022Observational
- Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.Annals of hematology · 2021Article
- Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2Journal of clinical and experimental hematopathology : JCEH · 2021Article
- Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors-A Strategy for Hematological Malignancies?Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 14 institutions in 2 countries.
Margherita MaffioliHematology Unit, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy.
Toni GiorginoBiophysics Institute (IBF-CNR), National Research Council of Italy, Milan, Italy.
Barbara MoraHematology Unit, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy.
Alessandra IurloHematology Division, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Elena ElliHematology Division and Bone Marrow Unit, Ospedale San Gerardo, Monza, Italy.
Maria Chiara FinazziDepartment of Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy.
Marianna CaramellaDepartment of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Elisa RumiDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Maria Cristina CarraroHematology and Transfusional Medicine Unit, ASST Fatebenefratelli Sacco, Milan, Italy.
Nicola PolverelliUnit of Blood Diseases and Stem Cell Transplantation, ASST Spedali Civili di Brescia, Brescia, Italy.
Mariella D'AddaDepartment of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.
Simona MalatoHematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy.
Marianna RossiDepartment of Hematology, Cancer Center, IRCCS Humanitas Research Hospital/Humanitas University, Rozzano, Italy.
Alfredo MolteniHematology Unit, ASST Cremona, Cremona, Italy.
Alessandro VismaraOnco-Hematology Unit, ASST-Rhodense, Rho, Italy.
Cinzia SissaDepartment of Hematology and Transfusion Medicine, ASST Mantova, Mantova, Italy.
Francesco SpinaHematology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Michela AnghilieriOncology Department, ASST Lecco, Lecco, Italy.
Daniele CattaneoHematology Division, Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Rossella RensoHematology Division and Bone Marrow Unit, Ospedale San Gerardo, Monza, Italy.
Marta BelliniDepartment of Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy.
Maria Luisa PioltelliDepartment of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Chiara CavalloniDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Daniela BarracoHematology Unit, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy.
Raffaella AccettaCytogenetics and Genetics Laboratory, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy; and.
Lorenza BertùDepartment of Medicine and Surgery, University of Insubria, ASST Sette Laghi-Ospedale di Circolo, Varese, Italy.
Matteo Giovanni Della PortaDepartment of Hematology, Cancer Center, IRCCS Humanitas Research Hospital/Humanitas University, Rozzano, Italy.
Francesco PassamontiDepartment of Medicine and Surgery, University of Insubria, ASST Sette Laghi-Ospedale di Circolo, Varese, Italy.
Ospedale di Circolo e Fondazione Macchi · ITAzienda Ospedaliera San Gerardo · ITAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITAzienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITHumanitas University · ITOspedale Papa Giovanni XXIII · ITUniversity of Insubria · ITUniversity of Pavia · ITASST Fatebenefratelli Sacco · ITAziende Socio Sanitarie Territoriali di LeccoFondazione IRCCS Istituto Nazionale dei Tumori · ITIstituti Ospitalieri di Cremona · ITUniversity of Milan · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overBiomarkersDuration of TherapyFemaleHumansItalyJanus Kinase InhibitorsMaleMiddle AgedMutationMutation RateNeoplasms, Second PrimaryNitrilesPrimary MyelofibrosisBiomarkersJanus Kinase InhibitorsNitrilesPyrazolesPyrimidinesruxolitinib
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.